Here are the 10-K annual reports from PMV Pharmaceuticals, Inc (PMVP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PMVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMVP filings page.
PMV Pharmaceuticals is a precision oncology company developing small-molecule, tumor-agnostic therapies targeting mutant p53, led by rezatapopt for the p53 Y220C mutation. In the Phase 2 pivotal PYNNACLE trial, rezatapopt achieved a 34% overall response rate in 103 efficacy-evaluable patients and a 46% response rate in 48 ovarian cancer patients, with median response durations of 7.6 and 8.0 months. Rezatapopt has FDA Fast Track and orphan drug designations, and the company plans to submit a New Drug Application for platinum-resistant or refractory TP53 Y220C ovarian cancer in the first quarter of 2027. PMV is also advancing additional p53-focused programs, building companion diagnostics with FoundationOne CDx, and preparing commercialization infrastructure and IP protection around its platform.